Latest News by Industry
AUSTIN, Texas (AP) _ Aeglea Biotherapeutics Inc. (AGLE) on Thursday reported a loss of $18.2 million in its third quarter.
The Austin, Texas-based company said it had a loss of 19 cents per share.
The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 24 cents per share.
The biopharmaceutical company posted revenue of $174,000 in the period.
The company's shares closed at $1.22. A year ago, they were trading at $7.49.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a AGLE">Zacks stock report on AGLE at https://www.zacks.com/ap/AGLE